Medtronic, Inc. has just announced that it has received FDA approval of the AneuRx® AAAdvantage™ abdominal aortic aneurysm (AAA) stent graft with Xcelerant® delivery system. The device is a next-generation, minimally-invasive endovascular system. Features, profiled by the company:
Enhancements to the new AAAdvantage system include:
— potentially broader proximal and distal sealing areas due to longer aortic bodies, longer and larger straight iliac limbs, and flared iliac limbs and extensions
— improved radiopaque markers
— contoured stents
These enhancements will provide greater patient applicability, help reduce the complexity of the procedure and upgrade the durability of the stent graft. Additional enhancements are planned for the near future.
Dr. Mark Farber, Associate Professor of Vascular Surgery and Interventional Radiology from University of North Carolina, noted the system’s ease of use. “The AneuRx AAAdvantage system demonstrates Medtronic’s continued commitment to the endovascular community and allows physicians to easily and precisely treat patients with a broad range of aneurysmal disease,” he said.
The AneuRx AAAdvantage system builds on the strong history developed with the original AneuRx AAA system, which has been available in the U.S. since 1999. More than 55,000 patients have received AneuRx stent grafts.